Showing 221-230 of 356 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Identifying regulators of primary human beta cell survival and proliferation | The Regents of the University of California, San Francisco | Rebecca Lee | Cures | 01-March-2024 to 28-February-2027 | $235.025,00 |
| Engineering Treg Signaling to Develop an Effective Cell Therapy for Type 1 Diabetes | The Regents of the University of California, San Francisco | Roberto Castro-Gutierrez | Cures | 01-March-2026 to 28-February-2029 | $285.000,00 |
| Allogeneic hypoimmunogenic Pancreatic Islets for Treatment of Diabetes in the Intra-Muscular Site | The Regents of the University of California, San Francisco | Tobias Deuse | Cures | 01-August-2024 to 31-July-2026 | $799.998,40 |
| Investigating MAFA governed mechanisms underlying β-cell functional maturation and dysfunction using hPSC-derived β-cells | The Regents of the University of California, San Francisco | Veronica Cochrane | Cures | 01-July-2024 to 28-February-2027 | $231.222,03 |
| Prediction of Cancer Immunotherapy Precipitated Autoimmune Diabetes | The Regents of the University of California, San Francisco | Zoe Quandt | Cures | 01-March-2025 to 28-February-2030 | $1.000.000,00 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-December-2026 | $1.808.522,70 |
| Project Tuyinza | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-April-2026 to 31-March-2029 | $643.550,00 |
| Quality, Equity & Outcomes Program | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-September-2026 to 31-August-2028 | $1.400.000,00 |
| Dissecting HLA Mechanisms in T1D, SLE, and MS Through High-Throughput Self-Antigen Profiling | The University of Chicago | Aly Khan | Cures | 01-September-2025 to 31-August-2026 | $150.000,00 |
| Interferons and the Integrated Stress Response: Converging Pathways in β Cell Dysfunction in Type 1 Diabetes | The University of Chicago | Charanya Muralidharan | Cures | 01-March-2026 to 28-February-2029 | $95.000,00 |